Journal
LEUKEMIA
Volume 34, Issue 2, Pages 499-509Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41375-019-0564-z
Keywords
-
Categories
Funding
- MEXT
- MEXT's Promotion Plan for the Platform of Human Resource Development for Cancer Project
- JSPS KAKENHI [15K15368, 16K09859, 17K16195, 17H04211, 18K08372, 18K16126, 18K16127, 18K16098, 19K08848]
- Takeda Science Foundation
- SENSHIN Medical Research Foundation
- Japan Leukemia Research Fund
- Grants-in-Aid for Scientific Research [19K08848, 18K16126, 16K09859, 18K16098, 18K16127, 18K08372, 17H04211, 15K15368, 17K16195] Funding Source: KAKEN
Ask authors/readers for more resources
Studies have shown that mutant calreticulin (CALR) constitutively activates the thrombopoietin (TPO) receptor MPL and thus plays a causal role in the development of myeloproliferative neoplasms (MPNs). To further elucidate the molecular mechanism by which mutant CALR promotes MPN development, we studied the subcellular localization of mutant CALR and its importance for the oncogenic properties of mutant CALR. Here, mutant CALR accumulated in the Golgi apparatus, and its entrance into the secretion pathway and capacity to interact with N-glycan were required for its oncogenic capacity via the constitutive activation of MPL. Mutant CALR-dependent MPL activation was resistant to blockade of intracellular protein trafficking, suggesting that MPL is activated before reaching the cell surface. However, removal of MPL from the cell surface with trypsin shut down downstream activation, implying that the surface localization of MPL is required for mutant CALR-dependent activation. Furthermore, we found that mutant CALR and MPL interact on the cell surface. Based on these findings, we propose a model in which mutant CALR induces MPL activation on the cell surface to promote MPN development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available